Market Overview

UPDATE: Morgan Stanley Downgrades C.R. Bard to Underweight on Lagging Organic Growth

Related BCR
Bard Agrees to Acquire Full Ownership of its Joint Venture in Japan
Benzinga's Top Upgrades
C.R. Bard Gains Full Ownership of Medicon, Expands in Japan (Zacks)

Morgan Stanley downgraded C.R. Bard (NYSE: BCR) from Equal-weight to Underweight with a $91 price target.

Morgan Stanley noted, "Bard's growth has steadily dropped over the past two years from 5% growth in 1Q11 to 1.5% growth in 3Q12. While utilization is certainly a factor, we attribute much of the slowdown to Bard's end markets, which are more heavily US focused, less differentiated and more discretionary than investors appreciate. Bard needs to invest in its internal and external pipeline as well as emerging markets to shift its growth profile but we do not see a catalyst for recovery in 2013. We are lowering our organic growth outlook from 2.8% to 1.5% in 2013."

C.R. Bard closed at $101.83 on Wednesday.

Latest Ratings for BCR

Sep 2015JMP SecuritiesMaintainsMarket Outperform
Aug 2015Goldman SachsUpgradesNeutralBuy
Aug 2015KeyBancInitiates Coverage onSector Weight

View More Analyst Ratings for BCR
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings


Related Articles (BCR)

Get Benzinga's Newsletters